Atención médica de calidadDescubra por qué Mayo Clinic es el mejor lugar para atenderse. Pide una cita.
Research in the laboratory of David R. Deyle, M.D., is aimed at developing gene and cell therapies for the treatment of genetic disorders through the correction and alteration of the genome in human stem cells. Dr. Deyle and colleagues are working on improved methods of targeted genomic editing using viral vectors for the precise alteration of the human genome. His research team focuses on the genetic modification of mesenchymal stem cells and induced pluripotent cells (iPSCs) and on defining molecular mechanisms that control stem cell differentiation for the regeneration of skeletal tissue. In addition, the team is developing oncolytic viral therapy using measles virus for the treatment of neurofibromatosis 1 (NF1) tumors.
The long-term goal of Dr. Deyle's research is to develop novel therapeutics for the treatment of genetic disorders. Corrected or modified human stem cells will be of particular importance in the development of regenerative medicine therapies, and the knowledge that is gained from understanding and treating genetic disorders can be applied to other more common diseases.
In addition, individuals with NF1 have very limited options for treatment of their tumors. The use of oncolytic viruses to inhibit or regress tumor growth is a novel therapy that has the potential to dramatically alter the treatment options for NF1 patients.
Infórmate sobre los ensayos clínicos que abordan preguntas científicas específicas sobre la salud humana y las enfermedades.
Ver mis estudios.
Explora todos los estudios de investigación en Mayo Clinic.
Ver las conclusiones revisadas por colegas que publiqué como resultado de mi investigación.